Clinical Trial

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, single-center, single-arm phase Ib clinical trial. The aim of this study is to assess the safety and efficacy of JS014 in combination with Toripalimab and transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). The primary endpoint is the safety and tolerability, while the secondary endpoints include objective response rate (ORR), disease control rate (DCR), time to progression (TPP), progression-free survival (PFS), and overall survival (OS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-18.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-09-12
Trial Details
NCT Number NCT06882876
Lead Sponsor Xiangya Hospital of Central South University
Collaborators: Shanghai Junshi Bioscience Co., Ltd.
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 20 participants
Start Date 2025-07-10
Primary Completion 2027-01-01 (estimated)
Study Completion 2029-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-19